Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05461378 · ClinicalTrials.gov registry record
PREP (Pre-Exposure Prophylaxis) of COVID-19
A clinical trial of COVID-19 and Immuno-Deficiency, sponsored by Ghady Haidar.
- Completed
- Registry status
- 138
- Enrollment target
- 1
- Study location
NCT05461378 is a study of COVID-19 and Immuno-Deficiency that has completed, run by Ghady Haidar. The registered enrollment target is 138 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05461378, a study of COVID-19 and Immuno-Deficiency, has completed, sponsored by Ghady Haidar.
- COMPLETED
- Registry status
- 138 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD in participant's blood, blood antibody levels, neutralizing antibodies against SARS-CoV-2 (the virus that causes COVID-19), and other blood responses related to the immune system and COVID-19. Investigators are collecting blood and may also collect other samples such as nose swabs, oral swabs, or saliva.
Conditions Studied
Interventions
- DRUG Evusheld
Study Locations (1)
Pennsylvania
- UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2022-07-26 |
| Est. Completion | 2024-01-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05461378
The ClinicalTrials.gov registry entry for NCT05461378 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Ghady Haidar, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Evusheld is the first listed.
NCT05461378 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05461378 about?
NCT05461378 is a clinical study titled "PREP (Pre-Exposure Prophylaxis) of COVID-19". This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD in participant's blood, blood antibody levels, neutralizing antibodies ...
What is the current status of trial NCT05461378?
This trial is currently completed. The enrollment target is 138 participants. The study started on 2022-07-26. Estimated completion is 2024-01-29.
What conditions does trial NCT05461378 study?
This clinical trial studies the following conditions: COVID-19, Immuno-Deficiency.
What interventions are being tested in trial NCT05461378?
The interventions under investigation include: Evusheld (DRUG).
Who is sponsoring clinical trial NCT05461378?
This trial is sponsored by Ghady Haidar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05461378 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.